News

Clinical Trials

Kimberly Redmond | Equities.com |

Newly-released data from an ongoing study of the COVID-19 vaccine from Pfizer Inc (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) shows the two-dose shot offered high levels of protection for at least six months after administration.

On Thursday, the companies released updated topline results from their Phase 3 trial, which found the vaccine had 91.3% efficacy against the virus, and said they plan to apply for full approval from the US Food and Drug Administration. Currently, all of the vaccines in use in the US have only Emergency Use Authorization (EUA) from the FDA.


AP News | Equities.com |

The 9-year-old twins didn’t flinch as each received test doses of Pfizer’s COVID-19 vaccine -- and then a sparkly bandage to cover the spot.

“Sparkles make everything better,” declared Marisol Gerardo as she hopped off an exam table at Duke University to make way for her sister Alejandra.

Researchers in the U.S. and abroad are beginning to test younger and younger kids to make sure COVID-19 vaccines are safe and work for each age. The first shots are going to adults who are most at risk from the coronavirus, but ending the pandemic will require vaccinating children too.


AP News | Equities.com |

Image source: Gencat, CC0, via Wikimedia Commons

By MARIA CHENG

LONDON (AP) — AstraZeneca’s repeated missteps in reporting vaccine data coupled with a blood clot scare could do lasting damage to the credibility of a shot that is the linchpin in the global strategy to stop the coronavirus pandemic, potentially even undermining vaccine confidence more broadly, experts say.

The latest stumble fo...


AP News | Equities.com |

WASHINGTON (AP) — AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.

In the study of 30,000 people, the vaccine was 79% effective at preventing symptomatic cases of COVID-19 — including in older adults. There were no severe illnesses or hospitalizations among vaccinated volunteers, compared with five such cases in participants who received dummy shots — a small number, but consistent with findings from Britain and other countries that the vaccine protects against the worst of the disease.


Kimberly Redmond | Equities.com |

Johnson & Johnson said findings from its late-stage clinical trial shows its COVID-19 vaccine completely protects against coronavirus-related hospitalization and death a month after vaccination.

Phase 3 trial data released Friday showed Johnson & Johnson’s single-dose vaccine is 66% effective at preventing moderate to severe illness and 85% protective against the most serious symptoms.